ArticleFrontiers in public health2026
Recognizing muscle health in healthy aging and non-communicable disease policy: a public health perspective.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population aging and the rising burden of non-communicable diseases (NCDs) place sustained pressure on health systems. In this perspective, I argue that muscle health-muscle mass, strength, and physical function-should be recognized as an explicit and prognostically distinct target within policies for healthy aging and NCD prevention. Two arguments distinguish this from generic physical activity promotion: muscle strength predicts mortality, regardless of activity level, and the most significant gains are produced by resistance and multicomponent training rather than by aerobic activity alone. I summarize randomized evidence, including trials with follow-up to 36 months, highlighting that the benefits are more pronounced among individuals with demonstrable functional impairment-a finding that strengthens, rather than weakens, the policy case. I identify three recurring policy gaps: the limited use of feasible assessment tools in primary care, fragmented prevention efforts that under-prioritize resistance training, and the near absence of functional capacity in global NCD frameworks. Drawing on experiences from Japan, Europe, North America, and Brazil, I propose five operational priorities and examine the practical constraints on delivery-equipment, financing, workforce, cultural barriers, and long-term adherence-alongside the limits of the economic evidence, so that policy ambition is matched to the strength of the data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.